2 results
Approved WMORecruiting
Primary Objectives 1. To evaluate the efficacy of clazakizumab in preventing all-cause composite allograft loss (including death) due to CABMR.2. To evaluate the efficacy of clazakizumab in slowing/preventing the progressive loss of kidney function…
Approved WMORecruiting
The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing renal disease progression in primary IgAN patients